NCT05437848View on ClinicalTrials.gov

Chinese Multiple Dose Escalation (MDE) High Dose Study

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

February 25, 2022

Primary Completion Date

December 12, 2022

Study Completion Date

December 12, 2022

Conditions

Diabetes

Interventions

DRUG

Experimental: Cotadutide

Cotadutide: subcutaneous (SC) injection

OTHER

Placebo

Placebo subcutaneous injection

Trial Locations (2)

210012

Research Site, Nanjing

510515

Research Site, Guangzhou

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY